pyrazolon
structur
motif
critic
element
drug
aim
differ
biolog
endpoint
medicin
chemistri
research
synthes
druglik
pyrazolon
candid
sever
medicin
featur
includ
antimicrobi
antitumor
cn
central
nervou
system
effect
antiinflammatori
activ
meanwhil
sar
structureact
relationship
investig
drawn
attent
among
medicin
chemist
along
plenti
analogu
deriv
multipl
target
review
comprehens
summar
biolog
activ
sar
pyrazolon
analogu
wish
give
overal
retrospect
prospect
pyrazolon
deriv
pyrazolon
deleg
cluster
compound
nucleu
fig
investig
multipl
featur
applic
sinc
synthesi
antipyrin
knorr
numer
attent
caus
analges
antipyret
activ
pyrazolon
analogu
discoveri
featur
encourag
research
synthes
pyrazolon
deriv
similar
behavior
better
therapeut
action
nowaday
multipl
fda
approv
drug
contain
pyrazolon
nucleu
explor
fig
instanc
edaravon
use
free
radic
scaveng
treatment
amyotroph
later
sclerosi
al
aminophenazon
antipyret
antiinflammatori
activ
use
breath
test
measur
cytochrom
metabol
activ
liver
function
evalu
eltrombopag
use
treatment
low
blood
platelet
count
adult
idiopath
chronic
immun
thrombocytopenia
dichloralphenazon
use
relief
tension
vascular
headach
metamizol
use
periop
pain
cancer
pain
acut
injuri
form
pain
consid
strongest
antipyret
sever
investig
small
molecul
contain
pyrazolon
regard
drug
candid
includ
sulfamazon
propyphenazon
nifenazon
regard
pyrazolon
deriv
import
underlin
enorm
divers
class
synthet
pyrazolon
publish
exist
studi
pharmacolog
investig
review
concis
critic
account
focus
properti
pyrazolon
antimicrobi
antitumor
cn
effect
antiinflammatori
antioxid
antitubercular
antivir
lipidlow
antihyperglycem
agent
protein
inhibitor
summar
advanc
pyrazolon
deriv
well
sar
current
exist
review
pyrazolon
deriv
mainli
concern
catalyt
asymmetr
synthesi
coordin
comprehens
review
bioactiv
sar
studi
still
vacant
review
order
fill
gap
systemat
summar
biolog
activ
sar
could
benefici
research
design
novel
pyrazolon
deriv
addit
dock
analysi
use
explain
interact
typic
pyrazolon
deriv
potenti
target
give
visual
appreci
role
pyrazolon
group
play
bioactiv
recent
advanc
synthesi
pyrazolon
report
literatur
condens
hydrazin
bketoest
compound
classic
method
synthesi
pyrazolon
scheme
catalyt
condit
usual
use
organ
base
like
piperidin
inorgan
base
like
nah
system
boil
ethanol
methanol
solvent
nucleu
pyrazolon
wide
use
ulteriorli
synthes
broad
rang
deriv
includ
spiroheterocycl
acyl
product
featur
multipl
reactiv
site
electrophil
substitut
posit
pyrazolon
effect
synthet
rout
construct
pyrazolon
link
chiral
group
pyrazolon
addit
import
synthon
bunsatur
pyrazolon
r
c
cr
c
nr
c
transform
divers
pyrazolon
r
c
cr
undergo
addit
acceptor
gener
pyrazol
analogu
broadspectrum
pharmacolog
properti
pyrazolon
deriv
report
includ
antimicrobi
antitumor
cn
activ
antiinflammatori
antioxid
antitubercular
antivir
lipidlow
antihyperglycem
protein
inhibitori
activ
pyrazolon
deriv
report
show
signific
antimicrobi
activ
multipl
type
bacteria
fungi
gener
antibacteri
effect
pyrazolon
better
antifung
effect
inhibitori
activ
gram
posit
gram
gram
neg
gram
strain
distinct
well
bacteri
cell
membran
gener
dens
wall
compris
sever
peptidoglycan
teichoic
acid
layer
gram
bacteria
adsorpt
biocid
molecul
occur
lipoteicho
acid
layer
character
charg
natur
abil
interact
heteroatom
biocid
molecul
gram
bacteria
lipid
layer
target
biocid
molecul
drug
resist
tradit
antibiot
arous
peopl
anxieti
superbacteria
attent
give
pyrazolon
pay
light
field
nasser
khalil
describ
schiff
base
compound
acetyl
glucosid
deriv
fig
exhibit
potent
inhibitori
effect
strain
penicillium
italicum
syncephalastrum
racemosum
aspergillu
fumigatu
bacillu
subtili
staphylococcu
aureu
escherichia
coli
dose
mgml
sar
could
deduc
analogu
nonsubstitut
ring
exhibit
strongest
activ
acetyl
glucosid
group
help
promot
inhibitori
effect
nglucosid
notabl
possibl
intramolecular
hbond
form
carbonyl
group
nh
moieti
improv
inhibit
triad
permeabl
solubl
potenc
analogu
chang
accordingli
padmavathi
colleagu
synthes
multipl
aminopyrazolon
aminoisoxazolon
aminopyrimidinon
analogu
evalu
bioactiv
thereinto
aminopyrazolon
deriv
fig
show
pronounc
antimicrobi
activ
tabl
sar
studi
elucid
analogu
aminohydroxypyrimidinon
n
ndimethyliminopyrimidinedion
show
weak
inhibitori
effect
compar
analogu
modifi
aminopyrazolon
aminoisoxazolon
group
addit
benzyl
sulfonyl
analogu
exhibit
strongest
inhibitori
effect
among
product
ali
cowork
synthes
antipyrin
deriv
fig
regard
prospect
inhibitor
tabl
sar
investig
expati
presenc
pyrazol
introduc
effect
moieti
includ
ecoch
ech
cl
thiophen
group
scaffold
show
signific
inhibitori
effect
hamama
teammat
describ
antibacteri
activ
sever
pyrazolon
analogu
among
compound
fig
hope
candid
e
coli
b
subtili
inhibit
zoom
diamet
valu
mm
respect
concentr
ppm
approxim
twofold
refer
drug
ampicillin
initiatori
sar
consid
introduct
piperidin
group
help
improv
antibacteri
effect
activ
antimicrobi
compound
produc
rasap
et
al
fig
exhibit
notic
antibiofilm
activ
toward
aureu
strain
tabl
compound
suppress
biofilm
format
staphylococcu
epidermidi
well
sar
studi
suggest
antibacteri
scaffold
acquir
condens
carbonyl
compound
activ
methylen
group
pyrazolon
substitut
group
ring
prove
potenti
activ
modif
develop
gadhav
colleagu
synthes
multifluorin
pyrazolepyrazolon
chromonepyrazolon
compound
fig
exert
favor
antibacteri
effect
tabl
wherea
compound
exhibit
poor
antifung
activ
profil
regard
sar
specul
multifluorin
substitut
contribut
antibacteri
modif
need
improv
antifung
effect
narayana
rao
et
al
design
synthes
sever
pyrazolon
analogu
fig
favor
activ
tabl
sar
author
disclos
amino
group
ring
pyrazolon
markedli
elev
inhibitori
effect
compar
methyl
antimicrobi
sequenc
r
group
pposit
phenylhydrazin
gener
summar
cl
br
ome
oc
h
abdel
reheim
baker
synthes
multipl
pyrazolon
deriv
screen
antimicrobi
activ
among
compound
exhibit
strongest
antibacteri
antifung
activ
compound
fig
show
signific
antifung
effect
tabl
result
antimicrobi
test
conclud
introduct
activ
substitut
pyrano
pyridazin
pyrimidin
promot
antimicrobi
activ
pyrazolon
nucleu
differ
degre
alkhaldi
et
al
synthes
pyrazolon
deriv
fig
multipl
antimicrobi
effect
tabl
concern
sar
meta
dichloro
phenyl
group
benzen
ring
schiff
base
help
improv
antibacteri
activ
subsequ
molecular
dock
interact
within
potenti
target
synthas
fig
provid
evid
antimicrobi
effect
pyrazolon
moieti
made
differ
bind
model
glucosamin
inhibitori
potenc
signific
well
bhattacharje
colleagu
present
pyrazolon
compound
fig
exhibit
favor
inhibitori
effect
bacillu
cereu
mic
valu
mgml
respect
suppress
growth
klebsiella
pneumonia
mic
valu
mgml
respect
preliminari
sar
extract
result
pyrazolon
group
necessari
antibacteri
activ
group
ring
potenti
effect
substitu
group
anoth
research
report
pyrazolon
deriv
fig
potent
compound
antibacteri
activ
antifung
activ
exert
differ
degre
tabl
regard
sar
obviou
compound
exhibit
antifung
activ
among
analogu
antibacteri
evalu
effici
inhibitor
mutan
typhi
b
subtili
respect
group
ring
potenti
activ
group
investig
say
et
al
synthes
activ
pyrazolonepyrazol
deriv
fig
antimicrobi
activ
explor
tabl
regard
sar
compar
inact
pyrazolon
deriv
nonsubstitut
benzen
ring
compound
exhibit
moder
activ
inhibit
zone
test
pyrazol
deriv
display
strongest
inhibitori
effect
indic
potenti
modif
method
investig
author
held
point
antimicrobi
effect
analogu
seem
like
trend
discrep
polar
interact
analogu
cellular
membran
inspir
structur
cholesterol
compound
fig
synthes
investig
antimicrobi
activ
shown
tabl
tabl
sar
indic
deriv
moieti
exhibit
higher
inhibitori
effect
deriv
contain
pyrazolyl
thiadiazin
moieti
addit
presenc
free
carbothiohydrazid
unit
enhanc
activ
compound
presenc
electrondon
group
edg
aromat
ring
promot
inhibitori
effect
compound
bihani
cowork
synthes
zwitterion
pyrazolon
analogu
fig
antimicrobi
properti
list
tabl
moder
inhibitori
effect
pseudomona
syringa
proteu
vulgari
also
report
sar
infer
electrophil
substitut
group
side
benzen
ring
could
strengthen
activ
orabi
teammat
synthes
phenylhydrazonopyrazolon
isoxazolon
analogu
antibacteri
agent
result
antibacteri
test
suggest
compound
contain
scaffold
pyrazolon
like
fig
exhibit
weak
antibacteri
effect
multipl
strain
interestingli
inhibitori
activ
promot
simultan
pyrazolon
moieti
replac
isoxazolon
furthermor
dock
studi
indic
cationp
interact
isoxazolon
analogu
arg
residu
play
crucial
role
stabil
cofactor
catalysi
flavin
adenin
dinucleotid
increas
antibacteri
effect
isoxazolon
antibacteri
effect
analogu
influenc
substitut
phenyl
ring
substitut
electron
withdraw
group
ewg
includ
f
cl
atom
select
increas
antibacteri
effect
aureu
compar
bulki
moieti
like
methyl
microorgan
acquir
metal
environ
use
mani
essenti
cellular
process
metal
abl
affect
bacteri
growth
vital
surviv
effect
remov
metal
use
metal
chelat
make
bacteri
cell
suscept
varieti
antibacteri
agent
caus
cell
lysi
loss
viabil
chelat
includ
edta
ethylenediaminetetraacet
acid
metal
complex
chalcon
flavonoid
attract
attent
field
recent
mani
research
group
made
unremit
effort
synthesi
character
transit
metal
chelat
pyrazolon
pyrazolon
like
form
sever
type
coordin
compound
due
sever
electronrich
donor
center
coordin
compound
contain
pyrazolonebas
ligand
report
superior
reagent
antimicrobi
agent
research
mn
iii
mixedligand
complex
bispyrazolon
ciprofloxacin
drug
publish
antimicrobi
outcom
show
ad
strain
microorgan
e
coli
serratia
marcescen
aureu
b
subtili
mixedligand
complex
contain
moieti
bispyrazolon
ciprofloxacin
exhibit
stronger
inhibitori
effect
compar
bispyrazolon
compound
fig
potenti
activ
antimicrobi
agent
sar
suspect
chelat
decreas
polar
central
atom
due
partial
share
posit
charg
donor
moieti
possibl
electron
deloc
whole
chelat
ring
complex
molecul
promot
hydrophob
charact
metal
chelat
liposolubl
henc
favor
permeat
lipoid
layer
cell
membran
microorgan
jadeja
cowork
synthes
multipl
pyrazolonebas
complex
evalu
bioactiv
consequ
indic
compound
fig
show
stronger
inhibitori
effect
b
subtili
deriv
dose
mm
compound
suppress
growth
b
subtili
strain
diamet
inhibit
zone
mm
schiff
base
deriv
pyrazolon
intrigu
attent
coordin
chemist
versatil
spacer
due
viabl
access
structur
divers
joseph
et
al
prepar
two
kind
copper
complex
deriv
fig
test
antimicrobi
activ
multipl
strain
result
show
compound
suppress
growth
stain
effect
quit
compar
standard
drug
includ
levofloxacin
moxifloxacin
deriv
effect
deriv
lunagariya
et
al
synthes
sever
organometal
platinum
ii
analogu
contain
pyrazolon
determin
bioactiv
among
analogu
compound
nair
cowork
prepar
metal
complex
deriv
pyrazolon
evalu
antimicrobi
potent
synthet
analogu
exhibit
antimicrobi
effect
differ
degre
among
compound
fig
promis
one
highest
zone
inhibit
ie
mm
measur
p
aeruginosa
aureu
e
coli
sar
research
suggest
metal
chelat
toxic
parent
ligand
microorgan
ident
experiment
condit
biolog
activ
complex
follow
order
chang
metal
ion
ni
ii
co
ii
zn
ii
cu
ii
schiff
base
ligand
centuri
malign
tumor
one
lead
caus
death
develop
new
antitumor
agent
less
drug
resist
side
effect
need
done
soon
possibl
recent
year
pyrazolon
deriv
metal
complex
attract
great
attent
research
potenti
antitumor
activ
less
drug
resist
side
effect
far
divers
pyrazolon
analogu
antitumor
potenc
report
factor
receptor
also
known
mainli
express
vascular
endotheli
cell
hematopoiet
stem
cell
highli
express
varieti
malign
tumor
play
signific
regulatori
role
metastasi
angiogenesi
tumor
take
target
search
inhibitor
provid
good
way
find
new
anticanc
drug
base
conserv
activ
bind
site
similar
interact
conform
ligand
sever
novel
inhibitor
develop
pyrazolon
play
import
role
well
tripathi
cowork
synthes
train
heterocyclicsubstitut
pyrazolon
test
inhibitori
potenc
kinas
among
compound
fig
prove
potenti
deriv
inhibit
kinas
ic
valu
nm
sar
analogu
summar
replac
indol
ring
exhibit
potenc
increas
especi
posit
ring
inspir
exist
inhibitor
research
group
modifi
structur
introduc
substitu
gener
compound
investig
structur
modif
aromat
moieti
reveal
compound
fig
promis
anaplast
lymphoma
kinas
alk
inhibitor
ic
nm
sar
demonstr
plenti
halogen
substitu
group
aromat
ring
favor
alk
inhibitori
potenc
moreov
author
paid
attent
modif
heterocycl
moieti
sar
analysi
conclud
compound
bear
thiazol
increas
inhibit
alk
gu
et
al
prepar
seri
novel
pyridin
analogu
bear
pyrazolon
skeleton
evalu
cell
prolifer
activ
synthet
analogu
among
compound
fig
exhibit
favor
inhibitori
potenti
cmet
promis
analogu
significantli
inhibit
target
cmet
ic
mm
ic
mm
kinas
vitro
sar
analys
suggest
substitut
pyridin
amin
moieti
longer
polar
side
chain
hydrophil
group
could
improv
inhibitori
activ
receptor
tyrosin
kinas
cmesenchym
epitheli
transit
factor
cmet
vital
target
antitumor
therapi
play
crucial
role
occurr
develop
metastasi
angiogenesi
tumor
accord
theori
structurebas
drug
design
norman
cowork
design
synthes
seri
class
ii
cmet
inhibitor
among
deriv
fig
confirm
possess
excel
potenc
cmet
ki
nm
privileg
compound
demonstr
show
bind
affin
cmet
pdb
id
fig
also
kinas
pdb
id
fig
help
xray
analysi
cocryst
obvious
pyrazolon
moieti
play
crucial
role
occupi
activ
site
bind
pocket
form
pialkyl
val
cmet
hbond
asp
kinas
suggest
broad
prospect
pyrazolon
develop
antitumor
agent
futur
studi
provid
new
strategi
design
select
analogu
therefor
liu
et
al
synthes
cluster
pyrazolonebas
analogu
accord
compound
screen
select
class
ii
cmet
inhibitor
among
compound
fig
repres
activ
antitumor
agent
sar
investig
reveal
group
quinolin
region
pyridin
central
ring
b
side
chain
could
promot
select
activ
addit
polar
function
posit
pyrazolon
import
select
potenti
compound
fig
design
synthes
zhou
colleagu
inspir
structur
abozantinib
foretinib
cmet
inhibitor
ic
nm
show
antiprolif
effect
multipl
cancer
cell
line
respect
sar
investig
could
conclud
substitut
framework
foretinib
group
sustain
potent
antitumor
activ
addit
analogu
monodoubleedg
ring
b
activ
especi
ecf
posit
ring
b
effect
ech
eoch
group
antitumor
pyrazolon
deriv
human
sirt
sirtuin
rel
cell
senesc
apoptosi
metabol
prolifer
differenti
past
decad
emerg
target
cancer
chemotherapi
rel
import
sirt
famili
extens
research
mahajan
teammat
prepar
multipl
fivememb
ring
pyrazolon
analogu
sirtuin
inhibitor
among
product
compound
fig
show
inhibitori
activ
ic
valu
mm
mm
respect
addit
compound
display
promis
inhibitori
effect
ic
mm
accord
pharmacophor
investig
sar
sum
presenc
pyrazolon
ring
import
improv
inhibitori
effect
maintain
balanc
hbond
donor
acceptor
moieti
activ
analogu
introduct
bulki
hydrophob
benzen
group
posit
naphthalen
help
increas
activ
moreov
select
inhibit
significantli
elev
hbond
donor
nh
group
posit
replac
hbond
acceptor
report
pyrazolon
potenti
start
point
gener
rala
inhibitor
often
activ
human
cancer
cell
line
deriv
fig
promis
anticanc
candid
design
synthes
zhang
colleagu
consequ
abil
compound
induc
apoptot
death
cell
show
deriv
suppress
rala
accord
induc
accumul
ro
trigger
mitochondri
apoptosi
cell
markov
colleagu
design
synthes
compound
deriv
fig
exhibit
promis
activ
tabl
qsar
studi
reveal
geometr
topolog
moment
factor
effect
analogu
instanc
size
shape
molecul
contain
planar
benzen
group
posit
pyrazolon
show
superior
inhibitori
potenc
cell
test
favor
conform
moieti
interact
activ
site
herein
inhibitori
effect
target
mostli
depend
fragment
posit
form
hbond
activ
place
pyrazolon
deriv
well
known
compound
use
wide
prophylact
diseas
includ
cancer
ghorab
colleagu
synthes
varieti
pyrazolon
deriv
fig
inspir
determin
anticanc
activ
tabl
sar
studi
summar
potent
compound
belong
pyrimidin
deriv
especi
halogen
group
dube
colleagu
synthes
cluster
pyrazolon
heterocycl
deriv
evalu
cytotox
activ
vitro
result
brine
shrimp
lethal
assay
show
compound
display
favor
cytotox
activ
standard
cyclophosphamid
addit
compound
fig
found
promin
analogu
lethal
concentr
lc
valu
mgml
mgml
sulforhodamin
b
srb
assay
respect
sar
investig
impli
dimethoxi
substitut
ring
increas
antitumor
activ
group
hydrophob
hydrophil
play
signific
role
cytotox
activ
gouda
et
al
prepar
sever
pyrazol
analogu
test
cytotox
ehrlich
ascit
carcinoma
cell
eac
detail
cytotox
data
clearli
display
compound
tabl
sar
recapitul
introduc
ring
posit
benzothiophen
import
cytotox
activ
furthermor
order
antitumor
activ
compound
follow
fig
specul
group
cooet
posit
thiophen
ring
system
compound
increas
antitumor
activ
vya
colleagu
synthes
new
pyrazolon
base
complex
fig
first
time
suggest
potent
antitumor
agent
lung
cancer
cell
line
accord
evalu
cytotox
activ
cell
line
noncancer
rat
cardiomyocyt
cell
line
vitro
result
display
compound
fig
three
kind
pyrazolon
complex
fig
synthes
bakr
cowork
mtt
assay
outcom
impli
hl
exhibit
better
cytotox
activ
cell
line
ic
valu
mgml
respect
tabl
metal
complex
order
cytotox
found
zhang
colleagu
synthes
two
new
transit
metal
complex
deriv
potenti
antitumor
agent
accord
result
antitumor
determin
complex
fig
prove
exhibit
higher
cytotox
activ
ic
valu
mgml
human
esophag
cancer
cell
mgml
cervic
cancer
cell
hela
studi
suggest
complex
might
effect
agent
tumor
intric
pathogenesi
devast
effect
cn
diseas
still
challeng
research
find
novel
precursor
therapi
view
experi
develop
edaravon
sever
pyrazolon
taken
account
cn
agent
exist
literatur
mainli
focu
anticonvuls
antidepress
antiamyotroph
later
sclerosi
antialzheim
activ
inhibitori
effect
cn
relat
target
herein
summar
bioactiv
sar
synthet
deriv
wish
give
evid
pyrazolon
develop
cn
clinic
agent
epilepsi
chronic
neurolog
disord
syndrom
identifi
spontan
recurr
seizur
disrupt
period
less
normal
electroencephalograph
eeg
activ
behavior
current
anticonvuls
drug
chiefli
deriv
benzodiazepin
gaba
gaminobutyr
acid
analogu
pyrazolon
deriv
like
provid
novel
orient
drug
design
eldebss
et
al
synthes
pyrazolonebas
heterocycl
compound
monoamin
oxidas
mao
inhibitor
evalu
tryptamin
seizur
potenti
rat
result
manifest
compound
fig
promis
candid
tabl
viveka
et
al
prepar
pyrazolon
analogu
fig
favor
anticonvuls
activ
maxim
electroshock
me
test
compound
perform
best
protect
potenc
protect
ratio
signific
toxic
determin
dosag
mgkg
analges
test
show
weak
effect
compound
exhibit
moder
protect
reaction
time
mice
sar
studi
demonstr
exist
pyrazolon
moieti
elev
anticonvuls
potenc
analges
effect
dicl
substitu
group
heterocycl
system
promot
activ
wherea
slightli
less
activ
determin
analogu
dif
substitu
cluster
pyrazolon
analogu
synthes
assess
anticonvuls
antidepress
activ
abdelaziz
colleagu
compound
fig
display
potent
protect
potenc
pentylenetetrazol
ptz
induc
clonic
seizur
mice
dosag
level
mgkg
protect
ratio
respect
close
phenobarbit
sodium
mgkg
better
phenytoin
sodium
mgkg
preliminari
sar
studi
conclud
exist
cricoid
pyrazolon
group
increas
anticonvuls
effect
compar
linear
chainhydrazid
analogu
thiophen
acyl
moieti
potent
substitut
group
linear
chainhydrazid
analogu
perform
better
pyrazolon
antidepress
determin
merugumolu
cowork
prepar
multipl
pyrazolon
deriv
estim
antidepress
effect
vivo
consequ
demonstr
promis
deriv
fig
possess
remark
antidepress
activ
forc
swim
test
tail
suspens
test
tabl
rel
valu
magnitud
imipramin
sar
substitut
group
ring
aromat
hydrazin
exhibit
better
activ
substitut
group
pyrazolon
skeleton
effect
group
character
cellbas
high
throughput
screen
assay
target
mutant
cuzn
superoxid
dismutas
induc
toxic
aggreg
marker
amyotroph
later
sclerosi
al
orphan
neurodegen
diseas
without
cure
incid
per
per
year
year
diagnosi
death
cluster
pyrazolon
analogu
screen
evalu
antial
activ
fda
approv
drug
biochem
reagent
radhia
cowork
potent
skeleton
arylsulfanyl
pyrazolon
show
efficaci
compar
posit
control
radicicol
efficaci
test
express
cell
model
fig
typic
compound
decreas
mutant
aggreg
ed
valu
nm
weak
cytotox
effect
detect
ld
mm
sequent
research
seri
ether
analogu
metabol
stabil
synthes
effect
deriv
fig
show
superior
potenc
vitro
pharmacolog
pharmacokinet
featur
includ
protect
mutant
cytotox
ed
nm
good
perform
evalu
potassium
channel
mm
protect
primari
cortic
neuron
permeabl
rat
liver
microsom
cytochrom
isozym
moreov
vivo
efficaci
al
mous
model
pharmacokinet
profil
brain
penetr
investig
well
compound
mgkg
dosedepend
extend
surviv
mice
dose
mgkg
addit
compound
exhibit
favor
bloodbrain
barrier
penetr
effect
sar
research
reveal
size
electron
imper
featur
metaposit
deriv
potenc
analogu
reduc
sequenc
cl
cf
f
br
ph
base
structur
lead
compound
edaravon
tok
cowork
synthes
cluster
analogu
investig
potenti
antialzheim
activ
among
analogu
compound
fig
exert
potent
inhibitori
effect
detail
data
list
tabl
instanc
potent
ach
inhibit
agent
maob
inhibit
agent
initi
sar
could
summar
variat
substitu
group
strongli
affect
inhibitori
potenc
analogu
basic
nitrogen
atom
substitu
group
significantli
promot
ach
inhibitori
activ
addit
incorpor
ewg
increas
maob
inhibitori
activ
seen
dock
analysi
compound
prepar
similar
size
donepezil
fig
room
cyclopentanon
ring
occupi
pyrazolon
ring
provid
evid
activ
idea
captur
alzheim
diseas
major
inhibitori
neurotransmitt
mammalian
brain
gaba
deliv
primarili
gaba
receptor
gaba
receptor
consid
heteropentamer
transmembran
glycoprotein
span
extracellular
intracellular
region
inspir
pyrazolonebas
precursor
fig
hintermann
cowork
synthes
sever
analogu
ligand
benzodiazepin
bind
site
gaba
receptor
among
compound
fig
typic
compound
affin
ic
valu
gaba
receptor
gaba
receptor
gaba
bz
receptor
gaba
bz
receptor
nm
respect
howev
weak
activ
compound
observ
anxieti
model
vivo
suspect
due
high
level
clearanc
vitro
cl
int
rat
mlmin
mg
sar
studi
suggest
substitu
group
initi
maintain
purpos
investig
influenc
core
modif
variat
substitu
group
aromat
pyrazolon
moieti
lead
mix
result
correspond
analogu
weak
agonist
behav
antagonist
glycogen
synthas
kinas
regul
glycogen
metabol
well
known
involv
varieti
intracellular
signal
lot
inhibitor
use
treatment
cn
disord
includ
alzheim
diseas
ad
parkinson
diseas
stroke
traumat
brain
injuri
bipolar
disord
pyrazolon
deriv
chronicl
show
activ
target
well
promis
compound
fig
inhibit
ic
valu
nm
investig
demonstr
compound
possess
good
kinas
select
protect
effect
oxid
stress
mode
neuron
cell
locomotor
hyperact
mice
observ
sar
investig
indic
nonsubstitut
ring
advantag
activ
compound
exhibit
pronounc
inhibitori
effect
among
synthet
compound
interestingli
known
inhibitor
ie
bisindolmaleimid
hymenialdisin
fig
contain
moieti
structur
similar
pyrazolon
scaffold
indic
reason
use
pyrazolon
design
inhibitor
accord
structur
aaminoadip
acid
activ
agent
import
function
excitatori
amino
acid
receptor
subtyp
compound
fig
synthes
zimmermann
et
al
thought
reaction
howev
signific
agonist
antagonist
activ
test
compound
mglu
mglu
mglu
mglu
subtyp
observ
dose
mm
inappropri
pk
analogu
consid
potenti
reason
obstruct
interact
substitut
group
appropri
site
receptor
year
synthet
work
result
three
privileg
pyrazolon
deriv
antiinflammatori
potenc
name
antipyrin
propyphenazon
metamizol
still
wide
use
structur
characterist
methyl
group
attach
ring
nitrogen
atom
enhanc
activ
retain
antipyrin
newli
report
analogu
base
structur
market
antiinflammatori
drug
includ
antipyrin
aminophenazon
sever
pyrazolon
deriv
design
synthes
antiinflammatori
agent
thorough
understand
inflammatori
reaction
use
singl
mice
rat
model
evalu
analges
effect
gradual
fall
short
demand
investig
activ
target
involv
determin
includ
tnfa
etc
pyrazolon
antiinflammatori
effect
tend
inhibit
activ
cox
lox
catalyz
convers
arachidon
acid
prostaglandin
leukotrien
meanwhil
phosphatas
inhibitori
pyrazolon
also
disclos
indic
potenti
pyrazolon
motif
field
structur
similar
pyrazolon
select
inhibitor
celecoxib
also
provid
possibl
develop
potenti
clinic
candid
gastrointestin
side
effect
exist
usag
inhibitor
cardiovascular
side
effect
inhibitor
suggest
research
consid
inhibitori
potenc
antiinflammatori
agent
stori
develop
imrecoxib
concept
moder
select
enzym
report
refer
seen
bind
affin
model
celecoxib
pyrazolon
deriv
fig
pyrazolon
group
maintain
similar
pialkyl
effect
electron
group
alkyl
group
pocket
residu
compar
pyrrazol
ring
properti
similar
aromat
ring
carbonyl
group
pyrrazol
favor
hydrogen
acceptor
feasibl
form
potenti
hbond
alkalin
amino
acid
like
arginin
lysin
histidin
meanwhil
amino
group
hydrogen
donor
easi
form
hydrogen
bond
residu
like
glutamin
fig
cluster
pyrazolon
amino
pyrimidin
deriv
fig
synthes
antr
cowork
obviou
antiinflammatori
potenc
carrageenaninduc
rat
paw
edema
model
tabl
regard
sar
contrast
substitut
chlorin
nitro
antiinflammatori
effect
analogu
significantli
promot
electrondon
group
aminopyrimidin
benzen
ring
hydroxyl
methoxi
dimethylamin
nadia
colleagu
synthes
multipl
pyrazolonepyridazin
conjug
screen
antiinflammatori
activ
vivo
vitro
compound
fig
exhibit
strongest
antiinflammatori
activ
test
carrageenaninduc
mice
paw
edema
model
inhibit
test
tabl
also
inhibit
product
inflammatori
cytokin
includ
tnfa
serum
sar
studi
show
replac
bulki
aliphat
secondari
amin
morpholin
exert
good
antiinflammatori
effect
mannich
base
deriv
mmolkg
fig
display
remark
antiinflammatori
effect
carrageenaninduc
acut
albino
rat
paw
edema
model
inhibitori
rate
respect
h
administr
preliminari
sar
demonstr
analogu
contain
ewg
mannich
base
phenyl
ring
posit
especi
sulfon
group
enhanc
activ
abbadi
cowork
synthes
new
pyridin
pyran
indazol
pyrazolon
ring
among
synthet
product
indazol
deriv
mgkg
fig
obvious
suppress
swell
rat
hind
paw
induc
h
inject
carrageenan
inflammatori
inhibit
rate
respect
indic
excel
antiinflammatori
activ
seri
one
analogu
prepar
determin
antiinflammatori
effect
outcom
show
deriv
fig
prove
superior
inhibitori
potenc
target
inflamm
tabl
furthermor
deriv
also
exhibit
favor
antiinflammatori
effect
carrageenan
induc
rat
paw
edema
model
ed
valu
mgkg
vivo
respect
regard
sar
pyrazolon
contain
methyl
group
urea
substitut
carbonyl
pose
impact
cox
enzym
inhibit
substitu
ureaphenyl
group
ring
activ
contain
chlorin
posit
unsubstitut
urea
moreov
thiourea
deriv
impart
strengthen
activ
compar
urea
guanidin
ashraf
et
al
success
prepar
two
seri
pyrazolon
analogu
test
antiinflammatori
effect
vivo
vitro
deriv
fig
display
excel
inhibitori
activ
tabl
well
potent
edema
inhibit
sar
investig
show
compound
unsatur
moieti
allyl
aryl
group
maintain
stronger
activ
alkyl
group
thiourea
analogu
also
improv
antiinflammatori
potenc
presenc
bulki
hydrophob
cyclohexyl
group
el
say
colleagu
design
synthes
novel
heterocycl
deriv
contain
antipyrin
pyrazolon
framework
pharmacolog
test
result
reveal
deriv
fig
exhibit
signific
antiinflammatori
activ
differ
degre
vivo
vitro
tabl
sar
studi
indic
presenc
dioxol
ring
system
ncontain
heterocycl
amin
attach
methyl
group
antipyrin
structur
essenti
activ
case
compound
cluster
novel
pyrazolon
analogu
contain
aminosulfonyl
group
synthes
investig
antiinflammatori
potenc
outcom
show
three
compound
fig
potent
antiinflammatori
agent
exert
strong
inhibitori
effect
tabl
fahmi
et
al
test
antiinflammatori
effect
sever
novel
osubstitut
salicylamid
among
analogu
pyrazolon
deriv
fig
exhibit
moder
antiinflammatori
activ
carrageenaninduc
edema
model
multipl
bioactiv
test
result
indic
pyrazolon
structur
similar
group
pyrazol
could
potenti
substitut
golebiowski
cowork
synthes
novel
monocycl
pyrazolon
investig
inhibit
inflammatori
cytokin
outcom
show
compound
fig
significantli
reduc
express
tnfa
induc
lipopolysaccharid
lp
ic
valu
nm
furthermor
sar
studi
found
benzyl
amino
substitu
activ
aminopyridin
ring
nmethyl
substitut
pyrazolon
effect
ethyl
substitut
current
topic
inflammatori
reaction
beyond
analges
agent
immunoreact
target
also
involv
author
observ
interact
kinas
anoth
potenti
synthes
pyrazolon
deriv
fig
piperidin
ring
introduc
gain
better
pharmacokinet
paramet
carbonyl
group
pyrazolon
ring
prove
form
hbond
amin
group
ly
reveal
import
pyrazolon
moieti
type
inhibitor
free
radic
known
highli
reactiv
molecul
result
via
differ
biochem
reaction
bodi
free
radic
lead
metabolit
oxid
caus
differ
diseas
due
oxid
stress
pyrazolon
play
role
antioxid
activ
refer
antioxid
mechan
edaravon
c
c
doubl
bond
form
action
tautomer
carbonyl
group
pyrazolon
consid
import
light
structur
motif
schiff
base
deriv
fig
prepar
determin
antioxid
activ
deriv
exert
strong
antioxid
effect
ic
valu
mm
nonphenol
antioxid
agent
antioxid
effect
compound
consid
rel
format
proton
free
radic
methyl
group
schiff
base
pyrazolon
analogu
also
synthes
khan
et
al
among
product
phenol
product
fig
exhibit
signific
antioxid
effect
dpph
test
ic
valu
mm
respect
even
stronger
standard
drug
npropyl
gallat
ic
mm
sar
studi
reveal
doubl
phenol
group
substitut
analogu
perform
better
moieti
reduc
phenol
hydroxyl
group
substitut
stronger
gaffer
cowork
screen
antioxid
activ
cluster
thiazolylpyrazolon
deriv
azinobi
acid
abt
radic
cation
decolor
assay
compound
fig
mm
exhibit
strongest
antioxid
potenc
inhibit
respect
thereinto
compound
exhibit
better
activ
standard
inhibitor
ascorb
acid
inhibit
sar
investig
conclud
presenc
benzen
thiazol
ring
phenylthiocarbamoyl
moieti
along
core
pyrazolon
group
benefit
antioxid
effect
addit
substitu
group
thiazol
ring
better
methyl
substitut
tuberculosi
tb
airborn
infecti
diseas
caus
mycobacterium
tuberculosi
mtb
embodi
one
lead
caus
death
around
world
danger
spread
tb
primarili
associ
hiv
infect
rapid
develop
multidrugresist
mdr
strain
mtb
pyrazolon
precursor
report
show
potenti
antitubercular
activ
sivakumar
et
al
prepar
two
seri
hybrid
pyrazolon
analogu
determin
antitubercular
effect
potent
compound
fig
possess
appar
antitubercular
effect
ic
mgml
furthermor
sar
investig
indic
antitubercular
activ
compound
markedli
improv
absenc
doubl
bond
imin
side
chain
benzen
ring
end
pyrazolon
moieti
pethaiah
et
al
synthes
sever
analogu
water
onepot
process
investig
antitubercular
activ
mtb
vitro
mic
valu
potenti
compound
tabl
fig
better
clinic
drug
sar
show
replac
naryl
ring
deriv
contribut
antimycobacteri
activ
specif
analogu
contain
electronwithdraw
group
halogen
nitro
group
show
stronger
activ
compar
aryl
ring
contain
electrondon
group
methoxid
methyl
isopropyl
daniel
et
al
prepar
variou
pyrazol
analogu
evalu
antitubercular
activ
tuberculosi
compound
fig
potent
candid
tabl
sar
studi
demonstr
halogen
phenyl
ring
methyl
group
third
posit
pyrazol
ring
show
higher
antitubercular
effect
contain
alkyl
posit
two
seri
new
pyrazolon
analogu
prepar
assess
antimtb
activ
two
analogu
fig
contain
pchlorophenyl
ring
regard
promis
mtb
inhibitor
tabl
meanwhil
presenc
nmethylpiperazin
morpholin
group
remarkedli
improv
antimtb
effect
sever
mannich
base
schiff
base
pyrazolon
framework
synthes
result
show
analogu
fig
could
use
potenti
antitubercular
drug
due
extrem
high
activ
tabl
standard
ethambutol
ciprofloxacin
sar
studi
reveal
deriv
acyl
substitu
better
antimtb
abil
compris
ewg
nitro
chlorin
carboxyl
electron
donat
group
includ
hydroxyl
ahsan
cowork
design
diversifi
pyrazolon
deriv
aim
mtb
isoniazid
resist
mtb
among
compound
fig
exhibit
pronounc
inhibitori
effect
tabl
outstand
inhibitori
effect
isoniazid
resist
mtb
strain
observ
well
compound
reveal
show
strong
antibacteri
effect
simultan
sar
studi
reveal
naryl
electroneg
substitu
group
show
strongest
antitubercular
potenc
group
maximum
inhibit
compar
group
substitut
electron
donat
group
methoxyphenyl
exhibit
less
inhibit
follow
research
potent
compound
fig
select
novel
synthes
analogu
excel
activ
free
cytotox
mgml
appear
better
druglik
obtain
ad
imin
group
oxadiazol
phenyl
ring
sar
summar
ewg
produc
inhibitori
effect
multipl
virus
wide
exist
natur
threaten
public
health
pyrazolon
use
gener
antivir
agent
involv
antiorthopoxviru
antiproteaseresist
prion
protein
prpre
antisever
acut
respiratori
syndrom
sar
antibuffalopox
viru
bpxv
agent
fan
et
al
synthes
seri
pyrimidinepyrazolon
nucleosid
chimera
analogu
determin
antiorthopoxviru
activ
vitro
consequ
prove
compound
fig
exert
potent
antiorthopoxviru
effect
tabl
sar
studi
reveal
activ
enhanc
match
pyrazolon
moieti
kimata
cowork
report
synthesi
assess
multipl
prpre
accumul
inhibitor
accord
structur
edaravon
potent
compound
fig
display
prpre
inhibitori
effect
cell
ic
valu
nm
time
activ
quinacrin
effect
edaravon
furthermor
signific
sod
superoxid
dismutas
like
activ
observ
indic
potenti
novel
mechan
prpre
inhibitori
effect
sar
studi
demonstr
posit
class
substitut
directli
relat
potenc
suppress
accumul
prpre
substitut
nucleu
could
enhanc
inhibitori
activ
srinivasan
teammat
synthes
sever
spiropiperidinyl
pyrazolon
deriv
inspir
skeleton
potent
analogu
electron
donat
group
aromat
ring
kumar
cowork
synthes
multipl
pyrazolon
analogu
sarscoronaviru
cov
middl
east
respiratori
syndrom
mer
cov
proteas
inhibitor
among
compound
fig
exert
strongest
inhibitori
effect
sar
mer
ic
valu
mm
mm
respect
sar
studi
reveal
carboxyl
group
crucial
pharmacophor
presenc
either
posit
ring
moieti
b
critic
activ
meanwhil
chlorin
posit
ring
slightli
decreas
activ
seen
dock
studi
pyrazolon
group
compound
play
import
role
form
hbond
residu
glu
sar
pro
respect
chang
peopl
lifestyl
dietari
structur
incid
fatti
liver
increasingli
high
particular
nonalcohol
fatti
liver
diseas
nafld
serious
endang
peopl
life
health
howev
due
complex
pathogenesi
often
neglect
clinic
practic
pyrazolinon
deriv
reduc
cholesterol
lipid
accumul
bodi
regul
multipl
indic
ampk
fxr
therefor
import
improv
lipidlow
activ
modifi
structur
pyrazolon
pyrazolon
deriv
also
report
select
antagonist
nonsteroid
farnesoid
x
receptor
fxr
maintain
bile
acid
homeostasi
play
crucial
role
control
cholesterol
lipid
glucos
metabol
base
screen
known
fxr
modul
lead
compound
fig
ic
mm
identifi
help
homogen
timeresolv
fluoresc
htrf
assay
basi
modif
carri
accordingli
promis
compound
ic
mm
display
antagonist
capabl
higher
control
zguggulsteron
origin
analogu
respect
compound
prove
interact
fxralbd
high
bind
affin
potent
antagonist
activ
fxr
two
cell
test
platform
addit
compound
strongli
inhibit
regul
activ
chenodeoxychol
acid
fxr
target
gene
furthermor
compound
prove
play
role
lower
content
triglycerid
cholesterol
human
hepatoma
cell
cholesterolf
mice
sar
interpret
chang
substitu
pyrazolon
group
crucial
influenc
antagonist
effect
appropri
structur
optim
region
substanti
strengthen
activ
nafld
clinic
syndrom
identifi
hepat
steatosi
close
link
obes
insulin
resist
dyslipidemia
ampactiv
protein
kinas
ampk
function
energi
sensor
play
import
role
regul
lipid
metabol
accord
structur
lead
compound
fig
zhang
et
al
synthes
multipl
pyrazolon
deriv
ampk
activ
suppress
lipid
synthesi
reduc
lipid
accumul
obob
mice
potent
compound
directli
activ
kinas
domain
ampk
ec
valu
mmoll
act
nonselect
activ
ampk
complex
addit
compound
suppress
accumul
triglycerid
cell
dosedepend
outcom
demonstr
ampk
activ
could
part
treat
method
nafld
relat
metabol
disord
diabet
consid
rel
overindulg
lifestyl
thu
thought
major
health
concern
industri
countri
pyrazolon
disclos
antihyperglycem
multipl
target
includ
aldos
reductas
ar
aglucosidas
aamylas
antihyperglycem
activ
pyrazolon
deriv
explor
kee
et
al
potent
compound
mgkg
fig
caus
decreas
plasma
glucos
dbdb
mice
moreov
essenti
normal
level
glucos
mgkg
reduct
maintain
remark
reduct
mgkg
decreas
sar
could
conclud
substitut
methylsulfinyl
ethyl
benzyl
group
combin
trifluoromethyl
posit
pyrazolon
hydroxi
tautom
form
potent
antihyperglycem
agent
mice
addit
chemic
trap
four
seven
possibl
tautomer
form
heterocycl
monoand
dialkyl
acid
hydrogen
gave
sever
addit
potent
analogu
kadam
cowork
synthes
sever
pyrazolon
deriv
inhibitor
ar
compound
fig
display
promis
inhibitori
ic
valu
mm
regard
sar
possibl
note
hydrophob
group
like
benzen
ring
pyrazolon
advers
influenc
ar
inhibit
introduct
carbothioamid
group
increas
inhibitori
effect
simultan
exist
arbothioamid
moieti
substitu
group
first
posit
pyrazolon
compound
exert
best
activ
dock
analysi
suggest
substitut
group
gave
proper
placement
hydrophob
group
respect
bind
pocket
ar
avoid
poor
interact
size
substitut
small
occupi
bind
pocket
pyrazolon
moieti
compound
consid
play
role
form
hbond
residu
cy
eldebss
colleagu
prepar
seri
pyrazolon
act
aglucosidas
aamylas
inhibitor
among
compound
fig
compound
fig
display
strongest
inhibitori
effect
ratio
primari
sar
suspect
introduct
disubstitut
halogen
analogu
promot
inhibitori
effect
due
high
electroneg
moreov
multifluoro
substitut
ring
could
potenti
activ
group
addit
activ
mention
pyrazolon
shown
inhibit
protein
includ
k
atp
channel
protein
phosphodiesteras
pde
aromatas
dival
metal
transport
human
transform
growth
factor
tgf
indic
multipl
target
therapeut
action
favor
druglik
pyrazolon
deriv
drizin
cowork
design
synthes
cluster
pyrazolon
deriv
k
atp
channel
open
inspir
disclos
compound
skeleton
fig
togeth
investig
sar
conclud
cyclopentanon
left
hand
portion
area
deriv
potent
cyclohexanon
introduct
gemdimethyl
group
well
incorpor
oxygen
cyclohexanon
ring
left
hand
portion
molecul
elev
potenc
right
hand
portion
molecul
activ
promot
nhgroup
pyrazolon
replac
oxygen
atom
ochiai
et
al
synthes
sever
analogu
cyclic
pde
compound
fig
demonstr
potent
compound
inhibit
pde
pde
ic
valu
mm
respect
addit
signific
bronchodilatori
activ
observ
sar
studi
demonstr
presenc
pyrazolopyridin
engend
potenc
inhibit
pde
isoster
imidazopyridin
substitut
made
pyrazolopyridin
subunit
increas
wellbalanc
dual
pde
pde
member
pde
trypanosoma
brucei
describ
crucial
target
therapi
human
african
trypanosomiasi
parasit
diseas
caus
protozoan
pathogen
brucei
orrl
colleagu
explor
catechol
pyrazolinon
trypanocid
inspir
structur
motif
rolipram
scaffold
merg
premier
potent
compound
fig
select
ic
valu
mm
furthermor
help
homolog
model
dock
studi
guid
fragment
grow
parasitespecif
ppocket
uniqu
subpocket
extend
invari
glutamin
gln
protein
solvent
enzym
bind
site
fragment
grow
compound
fig
emerg
outstand
activ
inhibit
brucei
rhodesiens
ic
valu
nm
ic
valu
nm
sar
investig
elucid
pyrazolon
held
conjug
psystem
addit
possibl
interact
aromat
residu
bind
pocket
moreov
extend
alkyl
chain
analogu
enabl
reach
enter
ppocket
displac
water
length
ppocket
place
tetrazol
solventexpos
exit
pore
tetrazol
compound
form
hbond
tyr
stabil
conform
afterward
accord
structur
amata
cowork
design
synthes
cluster
deriv
poor
inhibitori
effect
detect
promis
pyrazolon
compound
fig
show
inhibit
dose
mm
indic
better
understand
subtl
structur
featur
necessari
optim
enzym
inhibit
yi
cowork
synthes
diversifi
pyrazolon
deriv
screen
aromatas
inhibit
effect
activ
compound
fig
show
ic
valu
nm
nm
respect
inhibit
compound
even
stronger
refer
letrozol
ic
nm
sar
analysi
indic
pyrazolon
moieti
could
inhibit
aromatas
bind
activ
site
bioactiv
result
prove
presenc
substitut
compound
good
inhibit
promis
compound
cyano
group
reveal
interact
import
residu
arg
met
aromatas
highthroughput
screen
pyrazolon
hit
ic
mm
fig
elabor
structur
motif
preliminari
hittolead
effort
gave
pyridyl
analogu
ic
mm
impart
sever
undesir
featur
includ
notabl
extend
conjug
motif
afford
intens
orang
color
well
michael
acceptor
featur
benzyliden
acarbon
investig
introduc
substitut
modifi
skeleton
promis
compound
ic
mm
distinguish
emin
absorpt
distribut
metabol
excret
adm
properti
inhibit
significantli
reduc
rat
microsom
metabol
stabil
markedli
hoist
compar
precursor
sar
analogu
impli
ewg
benzen
ring
slightli
prefer
electrondon
one
base
exist
inhibitor
guckian
colleagu
describ
seri
kinas
inhibitor
includ
pyrazolon
group
allow
replac
ubiquit
nitrogen
hbond
acceptor
within
core
carbonyl
without
remark
loss
biochem
activ
activ
compound
fig
inhibit
kinas
ki
valu
mm
suppress
pailuc
ic
valu
mm
sar
recapitul
carbonyl
moieti
pyrazolon
potent
captur
hbond
interact
key
residu
ly
ring
area
author
paid
attent
modifi
found
ring
substitut
pyridin
ring
could
elev
activ
contain
basic
nitrogen
occupi
hydrophob
pocket
aromat
ring
substitut
meta
posit
prove
superior
ortho
para
posit
posit
sensit
natur
substitut
prefer
small
hydrophob
substitu
group
without
branch
acarbon
consid
influenc
size
substitut
atom
hydrophob
pocket
bromo
group
select
suitabl
substitut
investig
asymmetr
synthesi
asymmetr
spiropyrazolon
deriv
hotspot
recent
year
investig
bioactiv
product
relationship
enantioisomer
activ
still
rare
bao
et
al
synthes
seri
dispirotriheterocycl
scaffold
deriv
screen
inhibitori
effect
worth
note
potent
compound
fig
two
chiral
center
import
inhibitori
potenc
exert
strong
inhibit
ic
valu
mm
whose
activ
stronger
enantiom
indic
import
asymmetr
cycliz
process
pyrazolon
core
one
explor
precursor
among
divers
fuse
heterocycl
capabl
multipl
role
differ
pathophysiolog
condit
accord
concept
gener
bioisoster
typic
synthet
rather
natur
motif
medicin
chemistri
pyrazolon
potenti
replac
multipl
moieti
similar
chemic
structur
bioactiv
includ
parazol
etc
provid
import
scaffold
drug
develop
versatil
molecul
immens
biolog
signific
pyrazolon
deriv
develop
sever
patholog
screen
includ
antimicrobi
antitumor
cn
effect
antiinflammatori
antioxid
antitubercular
antivir
protein
inhibitor
activ
sinc
long
develop
pyrazolon
deriv
regard
epitom
medicin
chemistri
start
antipyrin
sever
analogu
explor
precursor
design
method
evolv
structur
modif
fragment
base
drug
design
highthroughput
screen
simultan
develop
scienc
machin
learn
virtual
screen
combinatori
chemistri
technolog
shorten
time
filtrat
lead
compound
play
import
role
drug
design
futur
investig
privileg
scaffold
perspect
sar
last
sever
year
probabl
pyrazolon
scaffold
posit
establish
compound
librari
due
good
druglik
broad
bioactiv
properti
moreov
mention
articl
pyrazolon
group
maintain
properti
like
aromat
feasibl
form
pialkyl
effect
residu
potenti
target
carbonyl
group
pyrrazol
favor
hydrogen
acceptor
feasibl
form
potenti
hbond
provid
evid
import
pyrazolon
structur
motif
medicin
chemistri
pan
assay
interfer
compound
studi
consid
poor
druglik
compound
bring
fals
posit
result
pyrazolon
list
besid
toxic
pyrazolon
deriv
still
alarm
loss
harm
caus
side
effect
antipyrin
aminopyrin
includ
leukopenia
agranulocytosi
still
vivid
review
disclos
recent
role
pyrazolon
field
medicin
chemistri
discuss
insight
sar
studi
bind
conform
heterocycl
compound
varieti
target
intellig
help
explor
novel
pyrazolon
analogu
challeng
pathophysiolog
condit
nowaday
none
author
conflict
interest
disclos
lung
cancer
cell
line
abt
azinobi
